Cagent Vascular Launches the POINT FORCE Registry
Cagent Vascular, Inc. has recently made waves by initiating the POINT FORCE Registry, a promising post-market clinical follow-up study focused on their innovative Serranator PTA Serration Balloon Catheter. This exciting development marks a significant milestone in the field of endovascular interventions, particularly for patients suffering from Peripheral Artery Disease (PAD).
Study Overview and Objectives
The POINT FORCE Registry will recruit a minimum of 500 subjects across up to 30 medical centers in the United States. The primary aim of this study is to assess the safety and efficacy of Serration Angioplasty for the comprehensive treatment of PAD throughout the leg. By employing a prospective multicenter single-arm design, the registry aims to gather valuable data that can influence future clinical practices.
Defining Success in the POINT FORCE Registry
Device Success is set as the primary endpoint for this study. It encompasses the successful delivery, inflation, and deflation of the Serranator, as well as the retrieval of the device while ensuring a post-procedure residual stenosis of 30% or less. An independent angiographic core lab will evaluate these crucial outcomes, ensuring the study's integrity and reliability.
Leadership and Expert Involvement
The registry is spearheaded by esteemed co-principal investigators, S. Jay Mathews, MD, MS, and Michael Siah, MD, both of whom are prominent figures in cardiovascular care. Their extensive experience and leadership will undoubtedly bolster the credibility of this study. The first patient was enrolled at the University of Texas Southwestern (UTSW), marking an exciting beginning for the POINT FORCE initiative.
Insights from the Investigators
Dr. Siah expressed enthusiasm about the registry's launch, emphasizing the importance of the Serranator in clinical practice. The preliminary enrollment at UTSW showcases the significance of this study in evaluating the device's role within broader treatment strategies for PAD.
Anticipated Outcomes of the POINT FORCE Registry
“From previous studies, we've seen that the Serranator produces effective results with minimal complications,” stated Dr. Mathews. With this registry, the goal is to further investigate how Serranation can be integrated into everyday clinical applications. The focus will include various vessel territories, such as Iliac, Fem-Pop, Infra-Pop, and Infra-Malleolar areas.
The Impact of the Serranator Technology
Brian Walsh, Chairman and CEO of Cagent Vascular, highlights the disruptive nature of the Serranator technology despite its extensive application in over 20,000 procedures. He believes that the POINT FORCE Registry will showcase the advantages of Serranation, potentially reshaping clinical algorithms across the board. The anticipation within the Cagent Vascular team and their partners is palpable as they embark on this significant journey.
About Cagent Vascular, Inc.
Cagent Vascular, Inc. is at the forefront of innovative solutions for vascular interventions. The Serranator, an FDA-cleared device, employs proprietary stainless steel micro-serration technology to enhance arterial dilation. This innovative balloon delivers an unparalleled 1,000 times more point force compared to traditional balloon angioplasty methods. This cutting-edge technology is designed to facilitate effective luminal gain for various lesion morphologies, ultimately improving patient outcomes.
Frequently Asked Questions
What is the POINT FORCE Registry?
The POINT FORCE Registry is a multicenter study evaluating the safety and efficacy of the Serranator balloon catheter for treating Peripheral Artery Disease.
How many patients will be enrolled in the study?
The study aims to enroll at least 500 patients across multiple medical centers in the United States.
Who are the key investigators leading the study?
The study is led by Dr. S. Jay Mathews and Dr. Michael Siah, both experts in cardiovascular medicine.
What is the primary endpoint of the POINT FORCE Registry?
The primary endpoint is Device Success, defined by specific delivery and retrieval criteria, as well as maintaining a post-procedure stenosis of 30% or less.
What technology does the Serranator utilize?
The Serranator uses micro-serration technology to enhance balloon angioplasty procedures with significantly improved point force for arterial expansion.
